Medication info
Diamin XR Tablets (Metformin Hydrochloride)

Diamin XR Tablets (Metformin Hydrochloride)

Prescription medicationTabletOral
Ingredient · strength
Metformin Hydrochloride›500mg / 1 tablet
Manufacturer / importer
Dongkwang Pharmaceutical Co., Ltd.
Appearance
White, biconvex, rectangular extended-release tablet
Packaging
30 tablets/bottle, 300 tablets/bottle
Approval status
Active

MFDS item code 200610962 · Approved 2006.12.14

Summary

Main use
Treatment of type 2 diabetes mellitus in adults
Who takes it
Adults
Adult dose
The dose should be determined individually based on the drug's efficacy and tolerability in the patient, and should not exceed the recommended maximum daily dose. The usual starting dose is one metformin hydrochloride extended-release tablet 500mg once daily with the evening meal. Blood glucose levels should be measured after one week and the dose adjusted. Gastrointestinal adverse reactions may improve with gradual dose increases. The maximum dose is 2000mg per day. When increasing the dose, increase by 500mg each week; up to a maximum of 2000mg per day may be administered with the evening meal. If glycemic control is not achieved with a maximum of 2000mg once daily, consider administering 1000mg twice daily; both doses should be taken with meals. For patients already treated with metformin tablets, the initial dose of this formulation is the same as the daily dose of immediate-release metformin tablets. Switching to this formulation is not recommended for patients taking more than 2000mg per day of immediate-release metformin tablets. At treatment initiation and during dose adjustment, fasting blood glucose should be measured to assess response to treatment with this drug and determine the minimum effective dose. Blood glycated hemoglobin levels should be measured approximately every 3 months. The goal of treatment with this drug, whether used as monotherapy or in combination with a sulfonylurea or insulin, is to reduce fasting blood glucose and blood glycated hemoglobin levels to normal or near-normal levels using the minimum effective dose. Patients with renal impairment This drug may be used in patients with moderate stage 3a renal impairment (creatinine clearance [CrCl] 45≤~ <60ml/min or glomerular filtration rate (GFR) 45≤~ <60 mL/min/1.73 m2) who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustments. The starting dose is 500mg or 750mg once daily. The maximum daily dose is 1000mg. Renal function should be closely monitored every 3- 6 months. If creatinine clearance or glomerular filtration rate falls below 45ml/min or 45ml/min/1.73m2, respectively, treatment with this drug must be stopped immediately.

Ingredients

Manufacturer
Dongkwang Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of type 2 diabetes mellitus in adults

  • Type 2 diabetes with insufficient blood sugar control
View approved original text

This medication is used in adult patients with type 2 diabetes who do not achieve sufficient blood sugar control with diet and exercise, especially in overweight individuals. It can be used alone or in combination with other oral hypoglycemic agents or insulin to effectively assist in blood sugar control. Therefore, it plays an important role in diabetes management and is used to improve patients' blood sugar control.

How to take

Adult dose

The dose should be determined individually based on the drug's efficacy and tolerability in the patient, and should not exceed the recommended maximum daily dose. The usual starting dose is one metformin hydrochloride extended-release tablet 500mg once daily with the evening meal. Blood glucose levels should be measured after one week and the dose adjusted. Gastrointestinal adverse reactions may improve with gradual dose increases. The maximum dose is 2000mg per day. When increasing the dose, increase by 500mg each week; up to a maximum of 2000mg per day may be administered with the evening meal. If glycemic control is not achieved with a maximum of 2000mg once daily, consider administering 1000mg twice daily; both doses should be taken with meals. For patients already treated with metformin tablets, the initial dose of this formulation is the same as the daily dose of immediate-release metformin tablets. Switching to this formulation is not recommended for patients taking more than 2000mg per day of immediate-release metformin tablets. At treatment initiation and during dose adjustment, fasting blood glucose should be measured to assess response to treatment with this drug and determine the minimum effective dose. Blood glycated hemoglobin levels should be measured approximately every 3 months. The goal of treatment with this drug, whether used as monotherapy or in combination with a sulfonylurea or insulin, is to reduce fasting blood glucose and blood glycated hemoglobin levels to normal or near-normal levels using the minimum effective dose. Patients with renal impairment This drug may be used in patients with moderate stage 3a renal impairment (creatinine clearance [CrCl] 45≤~ <60ml/min or glomerular filtration rate (GFR) 45≤~ <60 mL/min/1.73 m2) who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustments. The starting dose is 500mg or 750mg once daily. The maximum daily dose is 1000mg. Renal function should be closely monitored every 3- 6 months. If creatinine clearance or glomerular filtration rate falls below 45ml/min or 45ml/min/1.73m2, respectively, treatment with this drug must be stopped immediately.

Precautions

This medication can rarely cause a serious condition called lactic acidosis. Lactic acidosis is a state of excessive lactate accumulation in the body, leading to acidity, which may be life-threatening and requires caution. Severe hypoglycemia may occur when this medication is used with insulin or sulfonylureas, so blood sugar changes must be closely monitored when used in combination. This medication should not be used in patients with moderate to severe renal impairment or in patients with acute conditions that affect renal function, such as dehydration, severe infections, or heart failure. Use of this medication should be discontinued before and after examinations involving iodine-based radiologic contrast agents, and should only be resumed after renal function has returned to normal. Patients with allergic reactions to any component of this medication or those with type 1 diabetes or diabetic ketoacidosis should not receive this medication. In cases of severe infections, major trauma, or unstable patient conditions around the time of surgery, the use of this medication should be temporarily halted, and it can be resumed when the patient's condition stabilizes and renal function returns to normal. Patients with very poor nutritional status or liver dysfunction, or those consuming excessive alcohol should avoid this medication, and it should also be avoided if there are specific risks during pregnancy. Regular kidney function testing should be done during treatment with this medication, and elderly patients should be monitored more frequently due to a higher risk of renal impairment. Vitamin B12 deficiency may occur, so it is advisable to check this through regular blood tests. This medication may cause gastrointestinal symptoms (nausea, vomiting, diarrhea, etc.), which are mainly observed at the beginning of treatment, but usually resolve over time. If severe gastrointestinal symptoms or dehydration occur, the medication should be temporarily stopped. The risk of lactic acidosis increases when this medication is taken with alcohol, so it is important to avoid drinking. The effect of this medication may be increased or decreased when used with certain drugs; therefore, if you are taking other medications, you must consult with your doctor or pharmacist. This medication crosses the placenta during pregnancy, so it should be decided whether to use it after consulting a specialist when blood sugar control is needed during pregnancy. If breastfeeding, this medication is secreted into breast milk, so careful consideration should be given regarding whether to continue breastfeeding or to stop the medication treatment. Safety and efficacy have not been established for children and adolescents under 17 years of age, so it is not recommended. In case of overdose, hypoglycemia does not occur, but the drug may accumulate in the body, increasing the risk of lactic acidosis, so immediate notification to healthcare professionals is required, and blood dialysis may be helpful if necessary. This medication should be swallowed whole without chewing or crushing, and it is normal for the tablet coating to be expelled in the stool. During treatment with this medication, regular meals and exercise, as well as regular monitoring of blood sugar and kidney function, are important, and immediate consultation with healthcare professionals is necessary if symptoms change.

Side effects

  • severe lactic acidosis
  • severe hypoglycemia
  • vitamin B12 deficiency
  • taste impairment
  • nausea
  • vomiting
  • diarrhea
  • abdominal pain
  • loss of appetite
  • erythema
Show 3 more
  • pruritus
  • urticaria
  • rash

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly closed container to protect it from air and moisture. It is advisable to maintain a storage temperature between 1 and 30 degrees Celsius (room temperature).

Appearance and packaging

Appearance

White, biconvex, rectangular extended-release tablet

Package unit

30 tablets/bottle, 300 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.